Athira Pharma (ATHA)

• Market cap: $11.9M
• 1 day: -1.78%
• 5 days: -10.59%
• 1 month: 8.57%
• 3 months: -4.40%
• 6 months: -48.03%
• Year to date: -44.74%
• 1 year: -88.08%
• 5 years: -98.22%
• 10 years: -98.22%
• Sector: Healthcare
• Industry: Biotechnology

About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Employees: 26

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

300% more call options, than puts

Call options by funds: $4K | Put options by funds: $1K

1.36% less ownership

Funds ownership: 46.35% [Q4 2024] → 44.99% (-1.36%) [Q1 2025]

4% less funds holding

Funds holding: 56 [Q4 2024] → 54 (-2) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

52% less capital invested

Capital invested by funds: $10.5M [Q4 2024] → $5M (-$5.51M) [Q1 2025]

65% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 20